NIPH Clinical Trials Search

UMIN ID: UMIN000001599

Registered date:25/12/2008

CHP-MAGE-A4 vaccine study for MAGE-A4-expressing cancer

Basic Information

Recruitment status Complete: follow-up complete
Health condition(s) or Problem(s) studiedMAGE-A4-expressing therapy-resistant cancer (non origin-limited)
Date of first enrollment2008/12/01
Target sample size6
Countries of recruitmentJapan
Study typeInterventional
Intervention(s)Subcutaneous injection of CHP-MAGE-A4 protein complex vaccine 100 microgram or 300 microgram,every two weeks, repeated at least six cycles


Primary OutcomeSafety:maximum-tolerable dose, dose-limting toxicity, profiles of adverse events. Efficacy: MAGE-A4-specific immune responses
Secondary OutcomeEfficacy:tumor responses, progression-free time, overall survival, response-duration time and time-to-progression

Key inclusion & exclusion criteria

Age minimum20years-old
Age maximumNot applicable
GenderMale and Female
Include criteria
Exclude criteria1.HIV-positives. 2.Double cancers. 3.Autoimmune disease. 4.History of serious hypersensitivity. 5.Active CNS metastasis. 6.Lasting less than four weeks from the previous chemotherapy, systemic corticostoroid, immuno-suppressive or -stimulating agents, radiotherapy, or surgery to primary tumors 7.Pregnant or lactating. 8.Inappropriate for study entry judged by an attending physician.

Related Information


public contact
Name Shinichi Kageyama
Address 2-174, Edobashi, Tsu, Mie, 514-8507 Japan Japan
Telephone 059-231-5280
Affiliation CHP-MAGE-A4 clinical trial registry Cancer vaccine, Mie Universituy
scientific contact
Name Hiroshi Shiku
Address 2-174, Edobashi, Tsu, Mie, 514-8507 Japan Japan
Telephone 059-231-5187
Affiliation Mie University Graduate School of Medicine Immuno-Gene Therapy